TN2016000253A1 - [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis. - Google Patents

[1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis.

Info

Publication number
TN2016000253A1
TN2016000253A1 TN2016000253A TN2016000253A TN2016000253A1 TN 2016000253 A1 TN2016000253 A1 TN 2016000253A1 TN 2016000253 A TN2016000253 A TN 2016000253A TN 2016000253 A TN2016000253 A TN 2016000253A TN 2016000253 A1 TN2016000253 A1 TN 2016000253A1
Authority
TN
Tunisia
Prior art keywords
leishmaniasis
protozoan
triazolo
treatment
pyrimidine derivatives
Prior art date
Application number
TN2016000253A
Other languages
English (en)
Inventor
Agnes Biggart
Fang Liang
Casey Jacob Nelson Mathison
Valentina Molteni
Advait Suresh Nagle
Frantisek Supek
Vince Yeh
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52302387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2016000253(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2016000253A1 publication Critical patent/TN2016000253A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
TN2016000253A 2013-12-19 2014-12-18 [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis. TN2016000253A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361918089P 2013-12-19 2013-12-19
PCT/US2014/071077 WO2015095477A1 (en) 2013-12-19 2014-12-18 [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis

Publications (1)

Publication Number Publication Date
TN2016000253A1 true TN2016000253A1 (en) 2017-10-06

Family

ID=52302387

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2016000253A TN2016000253A1 (en) 2013-12-19 2014-12-18 [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis.

Country Status (41)

Country Link
US (6) US9303034B2 (enExample)
EP (1) EP3083627B1 (enExample)
JP (1) JP6392352B2 (enExample)
KR (1) KR102354082B1 (enExample)
CN (1) CN106029666B (enExample)
AP (1) AP2016009329A0 (enExample)
AR (1) AR098844A1 (enExample)
AU (1) AU2014364565B2 (enExample)
BR (1) BR112016014004B1 (enExample)
CA (1) CA2932870C (enExample)
CL (1) CL2016001421A1 (enExample)
CR (1) CR20160334A (enExample)
CU (1) CU24379B1 (enExample)
CY (1) CY1121060T1 (enExample)
DK (1) DK3083627T3 (enExample)
EA (1) EA030823B1 (enExample)
EC (1) ECSP16067921A (enExample)
ES (1) ES2701087T3 (enExample)
GT (1) GT201600131A (enExample)
HR (1) HRP20182021T1 (enExample)
HU (1) HUE040254T2 (enExample)
IL (1) IL246034B (enExample)
LT (1) LT3083627T (enExample)
MA (1) MA39186A1 (enExample)
MX (1) MX368072B (enExample)
MY (1) MY175865A (enExample)
NZ (1) NZ721650A (enExample)
PE (1) PE20160865A1 (enExample)
PH (1) PH12016501198A1 (enExample)
PL (1) PL3083627T3 (enExample)
PT (1) PT3083627T (enExample)
RS (1) RS58053B1 (enExample)
SG (1) SG11201604618TA (enExample)
SI (1) SI3083627T1 (enExample)
SV (1) SV2016005226A (enExample)
TN (1) TN2016000253A1 (enExample)
TW (1) TWI674263B (enExample)
UA (1) UA117046C2 (enExample)
UY (1) UY35903A (enExample)
WO (1) WO2015095477A1 (enExample)
ZA (1) ZA201604415B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104749A1 (es) * 2015-05-29 2017-08-09 Glaxosmithkline Ip Dev Ltd Imidazo[1,2-b][1,2,4]triazina sustituida, composición farmacéutica y combinación que lo comprenden, y su uso para la fabricación de un medicamento
ES2856899T3 (es) * 2015-08-07 2021-09-28 Glaxosmithkline Ip Dev Ltd Compuestos
US10399966B2 (en) 2016-01-21 2019-09-03 University Of Washington Compounds for treatment of trypanosomes and neurological pathogens and uses thereof
CN117105827A (zh) 2017-03-27 2023-11-24 魁北克电力公司 用于电解质组合物中或用作电极添加剂的盐
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
EA039324B1 (ru) * 2017-11-06 2022-01-13 Новартис Аг 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
TW202028208A (zh) 2018-10-09 2020-08-01 瑞士商諾華公司 N-(4-氟-3-(6-(3-甲基吡啶-2-基)-[1,2,4]三唑并[1,5-a]嘧啶-2-基)苯基)-2,4-二甲基㗁唑-5-甲醯胺固體形式

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038396A (en) 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
DE3130633A1 (de) * 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
DE3224512A1 (de) 1982-07-01 1984-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
FR2652085A1 (fr) 1989-09-20 1991-03-22 Science Organisation Nouveau procede de synthese de derives d'oxazolopyridines.
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH0643588A (ja) * 1992-07-27 1994-02-18 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
JP3735741B2 (ja) * 1995-11-24 2006-01-18 株式会社大塚製薬工場 縮環ピリミジン誘導体
US6184235B1 (en) 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
WO1998010779A1 (en) * 1996-09-13 1998-03-19 New York University Method for treating parasitic diseases with proteasome inhibitors
US20030225036A1 (en) 2000-03-20 2003-12-04 Aleksandr Kolesnikov Non-amidine containing protease inhibitors
MXPA02010763A (es) 2000-06-14 2003-03-10 Warner Lambert Co Heterociclicos biciclos-6,5 fusionados.
WO2002036580A2 (en) 2000-10-31 2002-05-10 Lynn Bonham Benzoxazole lpaat- beta inhibitors and uses thereof
AU2002214505A1 (en) 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
AU2002225767A1 (en) 2000-11-28 2002-06-11 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
EA007339B1 (ru) 2001-07-27 2006-08-25 Кьюэрис, Инк. Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ
US7488598B2 (en) 2001-10-26 2009-02-10 Cornell Center For Technology Enterprise And Commercialization Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
ES2309213T3 (es) 2001-11-16 2008-12-16 Nippon Chemiphar Co., Ltd. Inhibidor de xantina-oxidasa.
WO2003045929A1 (en) 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
JP2007500160A (ja) * 2003-07-30 2007-01-11 ラボラトリオス・エセ・ア・エレ・ベ・ア・テ・ソシエダッド・アノニマ 癌の予防および治療のための置換イミダゾピリミジン
WO2005013950A2 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
WO2005030206A1 (en) 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
US7432278B2 (en) 2004-03-08 2008-10-07 The University Of North Carolina At Chapel Hill Dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines as antiprotozoal agents
EP1833829A2 (en) 2004-12-23 2007-09-19 F. Hoffmann-Roche AG Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
CA2589877A1 (en) 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
WO2007017143A1 (en) 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
EP1912987A1 (en) 2005-08-01 2008-04-23 F. Hoffmann-Roche AG Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
US7345178B2 (en) 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US7438916B2 (en) 2005-10-14 2008-10-21 Virginia Tech Intellectual Properties, Inc. Therapeutic target for protozoal diseases
EP2023919A4 (en) 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
EP2054405B1 (en) 2006-07-11 2013-09-18 Daewoong Pharmaceutical Co., Ltd. Novel biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
WO2008100376A2 (en) 2007-02-15 2008-08-21 Sirtris Pharmaceuticals, Inc. Truncation variants of sirt1 and methods of use thereof
EP2139474A2 (en) 2007-03-27 2010-01-06 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
WO2008128968A1 (en) 2007-04-19 2008-10-30 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
EP2197979B1 (en) 2007-10-17 2016-12-07 Cheil Industries Inc. Novel compound for organic photoelectric device and organic photoelectric device including the same
RU2364597C1 (ru) 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
US8633019B2 (en) 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
CN102203067B (zh) 2008-08-25 2014-01-15 Irm责任有限公司 Hedgehog通路调节剂
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
UY32776A (es) * 2009-07-09 2011-02-28 Irm Llc Compuestos de imidazopirazinas sustituidas para el tratamiento de enfermedades parasitarias,composiciones farmacéuticas que los contienen y aplicación.
US20120157471A1 (en) 2009-09-01 2012-06-21 Pfizer Inc. Benzimidazole derivatives
CA2775354C (en) * 2009-09-29 2019-01-15 Margaret Phillips Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase
US20130035304A1 (en) * 2010-01-29 2013-02-07 Walensky Loren D Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
US20130150351A1 (en) 2010-06-03 2013-06-13 Stanley T. Carmichael Methods and compositions for treating a subject for central nervous system (cns) injury
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 2-芳基咪唑并[1,2-b]嗒.2-苯基咪唑并[1,2-a]吡啶,和2-苯基咪唑并[1,2-a]吡衍生物
JP5999387B2 (ja) 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Crth2拮抗薬としてのピラゾール化合物
WO2013009827A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
MX370976B (es) 2011-11-11 2020-01-10 Gilead Apollo Llc Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos.
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
EP2822948B1 (en) * 2012-03-07 2016-04-06 Merck Patent GmbH Triazolopyrazine derivatives
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
AR091586A1 (es) 2012-06-28 2015-02-11 Fujifilm Corp Derivado de amida o su sal como inhibidor de la produccion de colageno
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
US9896443B2 (en) 2012-08-21 2018-02-20 Peter Maccallum Cancer Institute Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases

Also Published As

Publication number Publication date
US20160303129A1 (en) 2016-10-20
ZA201604415B (en) 2017-09-27
HRP20182021T1 (hr) 2019-01-25
US10596175B2 (en) 2020-03-24
PL3083627T3 (pl) 2019-02-28
AR098844A1 (es) 2016-06-15
AU2014364565B2 (en) 2017-06-15
NZ721650A (en) 2018-12-21
US20170333437A1 (en) 2017-11-23
US20150175613A1 (en) 2015-06-25
MX368072B (es) 2019-09-18
CN106029666A (zh) 2016-10-12
AU2014364565A1 (en) 2016-07-14
BR112016014004B1 (pt) 2022-11-01
HUE040254T2 (hu) 2019-02-28
JP6392352B2 (ja) 2018-09-19
IL246034B (en) 2020-02-27
US20210369716A1 (en) 2021-12-02
EA030823B1 (ru) 2018-10-31
ECSP16067921A (es) 2017-10-31
PT3083627T (pt) 2018-11-30
PH12016501198A1 (en) 2016-08-15
ES2701087T3 (es) 2019-02-20
SG11201604618TA (en) 2016-07-28
CN106029666B (zh) 2018-05-18
PE20160865A1 (es) 2016-09-03
LT3083627T (lt) 2018-12-27
US20190000852A1 (en) 2019-01-03
CU20160090A7 (es) 2017-05-10
CU24379B1 (es) 2019-02-04
MX2016008079A (es) 2016-09-16
TW201609734A (zh) 2016-03-16
CA2932870C (en) 2021-11-09
US20200179391A1 (en) 2020-06-11
US9303034B2 (en) 2016-04-05
GT201600131A (es) 2018-12-18
SI3083627T1 (sl) 2019-01-31
MY175865A (en) 2020-07-14
UA117046C2 (uk) 2018-06-11
IL246034A0 (en) 2016-08-02
SV2016005226A (es) 2019-04-23
KR102354082B1 (ko) 2022-01-24
EP3083627B1 (en) 2018-09-05
CA2932870A1 (en) 2015-06-25
CL2016001421A1 (es) 2016-12-30
EP3083627A1 (en) 2016-10-26
US10085989B2 (en) 2018-10-02
CY1121060T1 (el) 2019-12-11
AP2016009329A0 (en) 2016-07-31
BR112016014004A2 (enExample) 2017-08-08
US11123348B2 (en) 2021-09-21
TWI674263B (zh) 2019-10-11
JP2017501177A (ja) 2017-01-12
RS58053B1 (sr) 2019-02-28
CR20160334A (es) 2016-12-06
WO2015095477A1 (en) 2015-06-25
DK3083627T3 (da) 2019-01-02
US9700559B2 (en) 2017-07-11
UY35903A (es) 2015-07-31
KR20160093077A (ko) 2016-08-05
MA39186A1 (fr) 2017-11-30
EA201691271A1 (ru) 2016-12-30

Similar Documents

Publication Publication Date Title
TN2015000391A1 (en) Compounds and compositions for the treatment of parasitic diseases
NZ721650A (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
WO2014151630A3 (en) Compounds and compositions for the treatment of parasitic diseases
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA201201161A1 (ru) Пирролопиримидины в качестве ингибиторов cdk4/6
MX2020011079A (es) Forma cristalina de sulfato acido de (s)-n-(5-((r)-2-(2,5-difluoro fenil)-pirrolidin-1-il)-pirazolo[1,5-a]-pirimidin-3-il)-3-hidroxi pirrolidina-1-carboxamida.
EA201890473A1 (ru) Гетероарильные производные в качестве ингибиторов parp
PH12017501570B1 (en) Bicyclic ketone sulfonamide compounds
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
EA201290237A1 (ru) Киназные ингибиторы
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
MX2013012588A (es) Inhibidores de cinasa.
MX2014000536A (es) Compuestos de 4-piperidinilo para usarse como inhibidores de tanquirasa.
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
NZ626112A (en) Triazinone compound and t-type calcium channel inhibitor
MA35010B1 (fr) Inhibiteurs de la peptide déformylase
JOP20140372B1 (ar) مشتقات [4،2،1] ثلاثي أزولو[1،5-a] بيريميدين كمثبطات لبروتياسوم الأَوَالِي للاستخدام في علاج الأمراض الطفيلية كداء اللِّيشْمانِيَّاتِ